Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 16/20 | 0.57 |
| ▸ | IKZF2 | Q9UKS7 | 4/20 | 0.52 |
| ▸ | IKZF1 | Q13422 | 1/20 | 0.52 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.45 |
| ▸ | DRD2 | P14416 | 1/20 | 0.44 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.44 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.44 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.44 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.44 |
| ▸ | IKZF3 | Q9UKT9 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22536049 | 1.00 | CRBN (0.57) | CRBNIKZF2IKZF1CSNK1A1DRD2 | |
| SCHEMBL29641124 | 1.00 | CRBN (0.57) | CRBNIKZF2IKZF1CSNK1A1DRD2 | |
| SCHEMBL31160690 | 1.00 | CRBN (0.57) | CRBNIKZF2IKZF1CSNK1A1DRD2 | |
| SCHEMBL20046182 | 1.00 | CRBN (0.57) | CRBNIKZF2IKZF1CSNK1A1DRD2 | |
| Hydrochloric Acid SCHEMBL22581068 | 0.99 | CRBN (0.56) | CRBNIKZF2IKZF1CSNK1A1DRD2 | |
| SCHEMBL20046597 | 0.96 | CRBN (0.57) | CRBNIKZF2IKZF1CSNK1A1DRD2 | |
| Trifluoroacetic Acid SCHEMBL30939002 | 0.92 | IKZF2 (0.51) | CRBNIKZF2IKZF1CSNK1A1DDB1 | |
| SCHEMBL25328847 | 0.90 | CRBN (0.58) | CRBNIKZF2IKZF1CSNK1A1DRD2 | |
| SCHEMBL24717747 | 0.90 | IKZF2 (0.50) | CRBNIKZF2IKZF1DRD2ADRA1D | |
| SCHEMBL30720935 | 0.90 | IKZF2 (0.50) | CRBNIKZF2IKZF1DRD2ADRA1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115003295-B | Novel chroman derivatives having estrogen receptor degrading activity and uses thereof | 冰洲石生物科技公司 | 2025-05-06 | — | — | CN | disclosed |
| CN-114761003-B | Novel ureas having androgen receptor degrading activity and uses thereof | 冰洲石生物科技公司 | 2023-12-29 | — | — | CN | disclosed |
| CN-117042769-A | Substituted pyrrolopyrimidines and pyrazolopyrimidines as Bruton's Tyrosine Kinase (BTK) degrading agents | 冰洲石生物科技公司 | 2023-11-10 | — | — | CN | disclosed |
| US-20230150973-A1 | NOVEL UREAS HAVING ANDROGEN RECEPTOR DEGRADATION ACTIVITY AND USES THEREOF | ACCUTAR BIOTECHNOLOGY INC. (US) | 2023-05-18 | — | — | US | disclosed |
| US-20230135173-A1 | NOVEL SUBSTITUTED QUINOLINE-8-CARBONITRILE DERIVATIVES HAVING ANDROGEN RECEPTOR DEGRADATION ACTIVITY AND USES THEREOF | ACCUTAR BIOTECHNOLOGY INC. (US) | 2023-05-04 | — | — | US | disclosed |
| CN-115003295-A | Novel chroman derivatives having estrogen receptor degrading activity and uses thereof | 冰洲石生物科技公司 | 2022-09-02 | — | — | CN | disclosed |
| US-11420956-B2 | Ureas having Androgen Receptor degradation activity and uses thereof | ACCUTAR BIOTECHNOLOGY INC. (US) | 2022-08-23 | — | — | US | disclosed |
| CN-114761003-A | Novel ureas having androgen receptor degrading activity and use thereof | 冰洲石生物科技公司 | 2022-07-15 | — | — | CN | disclosed |
| CN-113329999-B | Novel substituted quinoline-8-carbonitrile derivatives having androgen receptor degrading activity and uses thereof | 冰洲石生物科技公司 | 2022-07-01 | — | — | CN | disclosed |
| US-11312702-B2 | Substituted quinoline-8-carbonitrile derivatives having androgen receptor degradation activity and uses thereof | ACCUTAR BIOTECHNOLOGY INC. (US) | 2022-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11420956-B2 | Ureas having Androgen Receptor degradation activity and uses thereof | AR, UTS2R, ESRRA | CRBN 1098/4885IKZF2 4069/4885IKZF1 2897/4885 |
| US-20230135173-A1 | NOVEL SUBSTITUTED QUINOLINE-8-CARBONITRILE DERIVATIVES HAVING ANDROGEN RECEPTOR DEGRADATION ACTIVITY AND USES THEREOF | AR, NR5A1, ESRRA | CRBN 409/4885IKZF2 4352/4885IKZF1 3668/4885 |
| US-11312702-B2 | Substituted quinoline-8-carbonitrile derivatives having androgen receptor degradation activity and uses thereof | AR, NR5A1, ESRRA | CRBN 357/4885IKZF2 4290/4885IKZF1 3450/4885 |
| US-20230150973-A1 | NOVEL UREAS HAVING ANDROGEN RECEPTOR DEGRADATION ACTIVITY AND USES THEREOF | AR, UTS2R, ESRRA | CRBN 1041/4885IKZF2 4315/4885IKZF1 3057/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.